Skip to main content
. Author manuscript; available in PMC: 2015 Jan 10.
Published in final edited form as: Mol Cancer Ther. 2013 Sep 12;12(11):2483–2493. doi: 10.1158/1535-7163.MCT-13-0486

Figure 2.

Figure 2

WIN downregulates Sp-regulated proliferative, survival (A) and angiogenic (B) gene products and Sp proteins (C) in SW480, RKO and HT-29 cells. Cells were treated with 2.5–7.5 μM of WIN for 48 hr, whole cell lysates were analyzed by western blots, and expression of Sp1, Sp3 and Sp4 protein was quantitated (C) relative to βactin (levels in the DMSO group were set at 1.0). Results are expressed as means ± SE (three replicate experiments), and significantly (p < 0.05) decreased proteins are indicated (*). Data in Figures 2A and 2B were from the same experiment.